Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February–May 2021
| Autor: | Lois Lamerato, Mark W Tenforde, Michael E. Smith, Brendan Flannery, Michael L. Jackson, Richard K. Zimmerman, Edward A. Belongia, Miwako Kobayashi, Goundappa K. Balasubramani, Mary Patricia Nowalk, Huong Q. McLean, Jennifer R. Verani, Stephanie J. Schrag, Jennifer P. King, Sara S Kim, Manish M. Patel, Jessie R Chung, Arnold S. Monto, Emily T. Martin, Lisa A. Jackson, Manjusha Gaglani, Kayan Dunnigan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
medicine.medical_specialty COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Population Medical care Internal medicine Outpatients Humans Immunology and Allergy Medicine RNA Messenger education Vaccines Synthetic education.field_of_study vaccine effectiveness SARS-CoV-2 business.industry Brief Report COVID-19 United States Vaccination AcademicSubjects/MED00290 Infectious Diseases mRNA Vaccines business |
| Zdroj: | The Journal of Infectious Diseases |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19–like illness or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥16 years, the VE of messenger RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%–95%) for full vaccination and 75% (55%–87%) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care. With the test-negative design used to evaluate protection from messenger RNA vaccines, vaccine effectiveness against coronavirus disease 2019 among outpatients aged ≥16 years was 91% (95% confidence interval, 83%–95%) for full vaccination and 75% (55%–87%) for partial vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|